IFNL4-∆G基因型对接受直接抗病毒药物治疗的丙型肝炎1型患者持续病毒学应答的影响。
Impact of IFNL4-∆G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals.
作者信息
Backus Lisa I, Shahoumian Troy A, Belperio Pamela S, Winters Mark, Prokunina-Olsson Ludmila, O'Brien Thomas R, Holodniy Mark
机构信息
Population Health Services, Department of Veterans Affairs, Palo Alto, CA 94304, USA.
Population Health Services, Department of Veterans Affairs, Palo Alto, CA 94304, USA.
出版信息
Diagn Microbiol Infect Dis. 2018 Sep;92(1):34-36. doi: 10.1016/j.diagmicrobio.2018.04.004. Epub 2018 Apr 14.
In direct acting antiviral (DAA)-treated HCV genotype 1, the sustained virologic response rate with the ∆G/∆G genotype of IFNL4 rs368234815 (86.8%) was significantly lower than with ∆G/TT (95.9%, P = 0.03) or TT/TT (98.6%, P = 0.01). The SVR odds ratio for ∆G/∆G compared to TT/TT was 0.10 (P = 0.03). IFNL4 genotype might predict DAA-response.
在接受直接抗病毒药物（DAA）治疗的丙型肝炎病毒1型（HCV genotype 1）患者中，携带IFNL4基因rs368234815的∆G/∆G基因型的持续病毒学应答率（86.8%）显著低于携带∆G/TT基因型（95.9%，P = 0.03）或TT/TT基因型（98.6%，P = 0.01）的患者。与TT/TT基因型相比，∆G/∆G基因型的持续病毒学应答优势比为0.10（P = 0.03）。IFNL4基因的基因型可能可以预测DAA治疗的反应。
Zotero 插件